Literature DB >> 11071809

Potentiating AZT activation: structures of wild-type and mutant human thymidylate kinase suggest reasons for the mutants' improved kinetics with the HIV prodrug metabolite AZTMP.

N Ostermann1, A Lavie, S Padiyar, R Brundiers, T Veit, J Reinstein, R S Goody, M Konrad, I Schlichting.   

Abstract

The 60-fold reduced phosphorylation rate of azidothymidine (AZT) monophosphate (AZTMP), the partially activated AZT metabolite, by human thymidylate kinase (TMPK) severely limits the efficacy of this anti-HIV prodrug. Crystal structures of different TMPK nucleotide complexes indicate that steric hindrance by the azido group of AZTMP prevents formation of the catalytically active closed conformation of the P-loop of TMPK. The F105Y mutant and a chimeric mutant that contains sequences of the human and Escherichia coli enzyme phosphorylate AZTMP 20-fold faster than the wild-type enzyme. The structural basis of the increased activity is assigned to stabilization of the closed P-loop conformation. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11071809     DOI: 10.1006/jmbi.2000.4175

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  7 in total

1.  Cancer suicide gene therapy with TK.007: superior killing efficiency and bystander effect.

Authors:  Ellen Preuss; Alexander Muik; Kristoffer Weber; Jürgen Otte; Dorothee von Laer; Boris Fehse
Journal:  J Mol Med (Berl)       Date:  2011-06-23       Impact factor: 4.599

2.  Structure-based in-silico rational design of a selective peptide inhibitor for thymidine monophosphate kinase of mycobacterium tuberculosis.

Authors:  Manoj Kumar; Sujata Sharma; Alagiri Srinivasan; Tej P Singh; Punit Kaur
Journal:  J Mol Model       Date:  2010-08-11       Impact factor: 1.810

3.  Evaluation of a UCMK/dCK fusion enzyme for gemcitabine-mediated cytotoxicity.

Authors:  Adam J Johnson; Melissa N Brown; Margaret E Black
Journal:  Biochem Biophys Res Commun       Date:  2011-11-10       Impact factor: 3.575

4.  Restoration of the antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus by delivery of engineered thymidylate kinase to T cells.

Authors:  Arnon Lavie; Ying Su; Mahmood Ghassemi; Richard M Novak; Michael Caffrey; Nikolina Sekulic; Christian Monnerjahn; Manfred Konrad; James L Cook
Journal:  J Gen Virol       Date:  2008-07       Impact factor: 3.891

5.  Fusion enzymes containing HSV-1 thymidine kinase mutants and guanylate kinase enhance prodrug sensitivity in vitro and in vivo.

Authors:  A Ardiani; M Sanchez-Bonilla; M E Black
Journal:  Cancer Gene Ther       Date:  2009-09-18       Impact factor: 5.987

6.  Design of Thymidine Analogues Targeting Thymidilate Kinase of Mycobacterium tuberculosis.

Authors:  Luc Calvin Owono Owono; Melalie Keita; Eugene Megnassan; Vladimir Frecer; Stanislav Miertus
Journal:  Tuberc Res Treat       Date:  2013-03-24

7.  Stabilization of Active Site Dynamics Leads to Increased Activity with 3'-Azido-3'-deoxythymidine Monophosphate for F105Y Mutant Human Thymidylate Kinase.

Authors:  Ian J Fucci; Kaustubh Sinha; Gordon S Rule
Journal:  ACS Omega       Date:  2020-01-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.